Livalo and Zypitamag:
Livalo:
Contraindicated in:
Use Cautiously in:
CNS: amnesia, confusion, memory loss.
Derm: pruritus, rash, urticaria.
Endo: hyperglycemia.
GI: constipation, diarrhea, ↑ liver enzymes.
MS: myositis, back pain, extremity pain, myalgia, arthralgia, immune-mediated necrotizing myopathy, RHABDOMYOLYSIS.
Misc: (INCLUDING ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .
Drug-Drug:
Primary Hyperlipidemia and Mixed Dyslipidemia
Renal Impairment
Heterozygous Familial Hypercholesterolemia
Renal Impairment
Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: hmg coa reductase inhibitors (statins)
Absorption: Well absorbed (51%) following oral administration.
Distribution: unknown.
Protein Binding: >99%.
Metabolism/Excretion: Mostly metabolized by the liver; 15% excreted in urine, 79% excreted in feces mostly as metabolites.
Half-life: 12 hr.